Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Bellerophon Provides Update on INOpulse(R) Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided an update on the Company's ongoing Phase 2b randomized, double-blind,...

BLPH : 0.95 (-5.94%)
Moving Average Crossover Alert: Bellerophon Therapeutics (BLPH)

Bellerophon Therapeutics, Inc. (BLPH) could be a stock to avoid from a technical perspective

BLPH : 0.95 (-5.94%)
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse(R) for Treatment of Pulmonary Arterial Hypertension

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified...

BLPH : 0.95 (-5.94%)
Bellerophon Therapeutics: 2Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Wednesday reported a loss of $11.5 million in its second quarter.

BLPH : 0.95 (-5.94%)
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from...

BLPH : 0.95 (-5.94%)
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter...

BLPH : 0.95 (-5.94%)
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with...

BLPH : 0.95 (-5.94%)
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

EXAS : 61.64 (-2.88%)
BLPH : 0.95 (-5.94%)
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

BLPH : 0.95 (-5.94%)
ALXN : 125.89 (-0.53%)
Pick 3 Biotech Money-Spinning Bets Amid Market Instability

The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

OMED : 2.47 (-7.30%)
NVAX : 1.89 (-3.08%)
BLPH : 0.95 (-5.94%)
Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will...

BLPH : 0.95 (-5.94%)
Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018

Stock Monitor: Bellerophon Therapeutics Post Earnings Reporting

ICPT : 95.72 (-3.75%)
BLPH : 0.95 (-5.94%)
Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Bellerophon Therapeutics, Inc. (BLPH).

BLPH : 0.95 (-5.94%)
Bellerophon Therapeutics posts 4Q loss

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Thursday reported a loss of $24.2 million in its fourth quarter.

BLPH : 0.95 (-5.94%)
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter...

BLPH : 0.95 (-5.94%)
8-K: Bellerophon Therapeutics, Inc.

Document

BLPH : 0.95 (-5.94%)
10-Q: BELLEROPHON THERAPEUTICS, INC.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20

BLPH : 0.95 (-5.94%)
Bellerophon Therapeutics posts 3Q loss

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Tuesday reported a loss of $7.6 million in its third quarter.

BLPH : 0.95 (-5.94%)
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

BLPH : 0.95 (-5.94%)
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017.

BLPH : 0.95 (-5.94%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -3.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures ended the Friday session with most contracts 3 to 4 cents in the red. Nearby Dec wiped out all of last week’s gains, down 1.81% since last Friday. There was a little harvest pressure, and some garden variety profit taking after hit...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar